Back to discover
Drug

Domperidone

Approved medicine
ClassDopamine D2 receptor antagonistResearchOngoing clinical research

Also known as 5-chloro-1-(1-(3-(2-oxo-1-benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone, Equidone, Domperidona, Domperidonum.

RxNorm3626ChEMBLCHEMBL219916ATCA03FA03UNII5587267Z69
3
Active clinical trials
D(2) dopamine receptor
Primary target
3
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Drug Safety Update: Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension

Regulatory2026-07-21MHRA

Treatment Protocol for the Compassionate Use of Domperidone

Clinical trial2026-04-13Results expected Q4 2027 · ClinicalTrials.gov

Compassionate Use of Domperidone for Refractory Gastroparesis

Clinical trial2026-03-24Results expected Q4 2035 · ClinicalTrials.gov

Efficacy of Domperidone (a Prokinetic Agent) on Time in Range in Digestively Asymptomatic Type I Diabetic Patients With Delayed Gastric Emptying

Clinical trial2026-02-17Results expected Q2 2029 · ClinicalTrials.gov

Study of Effects of Preoperative Oral Domperidone on Gastric Residual Volume After Clear Fluid Ingestion in Patients Scheduled for Elective Surgeries: Prospective , Randomized ,Double Blinded Controlled Study

Clinical trial2023-04-20Completed · ClinicalTrials.gov

A Randomized Controlled Double-blinded of Effectiveness of Prokinetic Agents in Improving Abdominal Discomfort at Pre- and Post- Colonoscopy

Clinical trial2022-10-30Primary completion · ClinicalTrials.gov

The Effect of Antiemetics on Bowel Preparation Before Colonoscopy

Clinical trial2022-03-01Primary completion · ClinicalTrials.gov

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Prospective Pilot Study to Preliminarily Evaluate the Efficacy of Domperidone in Adult Chinese Subjects With Functional Dyspepsia

Clinical trial2020-07-31Completed · ClinicalTrials.gov

Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Domperidone 10mg QID for Reducing Progression of Disability in Patients With Secondary Progressive Multiple Sclerosis (SPMS)

Clinical trial2020-01-03Completed · ClinicalTrials.gov

Randomized, Controlled Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis

Clinical trial2019-02-01Completed · ClinicalTrials.gov

Drug Safety Update: Domperidone: no longer available without prescription

Regulatory2014-12-11MHRA

Drug Safety Update: Domperidone: risks of cardiac side effects

Regulatory2014-12-11MHRA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Domperidone
Aliases & brands
5-chloro-1-(1-(3-(2-oxo-1-benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinoneEquidoneDomperidonaDomperidonum
RxNorm CUI
3626
ChEMBL ID
CHEMBL219916
ATC codes
A03FA03
UNII
5587267Z69
Primary mechanism
Dopamine D2 receptor antagonist
Regulatory jurisdictions
mhra

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

D(2) dopamine receptor
DRD2 · P14416
ANTAGONISTDopamine D2 receptor antagonist

Regulatory timeline

3 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Authorities
MHRA
Total events
3
mhraMedicines and Healthcare products Regulatory Agency· 3 events
2026-07-21Safety communicationSafety
Drug Safety Update: Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension
Evidence ↗
2014-12-11Safety communicationSafety
Drug Safety Update: Domperidone: no longer available without prescription
Evidence ↗
2014-12-11Safety communicationSafety
Drug Safety Update: Domperidone: risks of cardiac side effects
Evidence ↗

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).

Clinical trials

30 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
30
registered trials across all phases
LATEST COMPLETION 2023
3
Active studies
3
Recruiting
22
Late-stage (III+)
16
Completed
11
Discontinued
PHASE DISTRIBUTIONn = 30
Early Phase 11Phase 12Phase 25Phase 2 / 31Phase 38Phase 45Phase N / A8

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

The Effect of Antiemetics on Bowel Preparation Before Colonoscopy

Unknown statusPH IVRenJi Hospitaln=2002022

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Prospective Pilot Study to Preliminarily Evaluate the Efficacy of Domperidone in Adult Chinese Subjects With Functional Dyspepsia

CompletedPH IVXian-Janssen Pharmaceutical Ltd.n=1602020

EFFECT OF LOW LEVEL LASER THERAPY VERSUS ELECTROACUPUNCTURE ON POSTNATAL SCANTY MILK SECRETION

CompletedPH IVCairo Universityn=602019

Therapeutic Efficacy of DA-9701 on Gastric Motility in Patients With Parkinson's Disease Evaluated by Magnetic Resonance Imaging: A Randomized Controlled, Double-Blind, Non-Inferiority Trial

CompletedPH IVSeoul National University Hospitaln=402016

Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis

Unknown statusPH IVLiangzhou Wein=602015

Recent completions

Trials that read out recently, adding to the completed evidence base.

Study of Effects of Preoperative Oral Domperidone on Gastric Residual Volume After Clear Fluid Ingestion in Patients Scheduled for Elective Surgeries: Prospective , Randomized ,Double Blinded Controlled Study

CompletedPH IIIAin Shams Universityn=402023

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Prospective Pilot Study to Preliminarily Evaluate the Efficacy of Domperidone in Adult Chinese Subjects With Functional Dyspepsia

CompletedPH IVXian-Janssen Pharmaceutical Ltd.n=1602020

Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Domperidone 10mg QID for Reducing Progression of Disability in Patients With Secondary Progressive Multiple Sclerosis (SPMS)

CompletedPH IIUniversity of Calgaryn=642020

Randomized, Controlled Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis

CompletedPH IIUniversity of Calgaryn=172019

EFFECT OF LOW LEVEL LASER THERAPY VERSUS ELECTROACUPUNCTURE ON POSTNATAL SCANTY MILK SECRETION

CompletedPH IVCairo Universityn=602019

Effect of Domperidone on Completion Rate of Vedio Capsule Endoscopy: a Prospective Randomized Controlled Study

CompletedN/AChildren's Hospital of Fudan Universityn=2002018
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.